- Home
- SGC vs VTYX Comparison
SGC vs VTYX Comparison
Compare SGC & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- VTYX
- Stock Information
- Founded
- SGC 1920
- VTYX 2018
- Country
- SGC United States
- VTYX United States
- Employees
- SGC N/A
- VTYX N/A
- Industry
- SGC Apparel
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SGC Consumer Discretionary
- VTYX Health Care
- Exchange
- SGC Nasdaq
- VTYX Nasdaq
- Market Cap
- SGC 155.7M
- VTYX 154.9M
- IPO Year
- SGC N/A
- VTYX 2021
- Fundamental
- Price
- SGC $10.89
- VTYX $2.38
- Analyst Decision
- SGC Strong Buy
- VTYX Buy
- Analyst Count
- SGC 3
- VTYX 4
- Target Price
- SGC $17.00
- VTYX $11.33
- AVG Volume (30 Days)
- SGC 54.4K
- VTYX 1.9M
- Earning Date
- SGC 08-05-2025
- VTYX 08-07-2025
- Dividend Yield
- SGC 5.04%
- VTYX N/A
- EPS Growth
- SGC N/A
- VTYX N/A
- EPS
- SGC 0.45
- VTYX N/A
- Revenue
- SGC $563,931,000.00
- VTYX N/A
- Revenue This Year
- SGC N/A
- VTYX N/A
- Revenue Next Year
- SGC $4.31
- VTYX N/A
- P/E Ratio
- SGC $24.71
- VTYX N/A
- Revenue Growth
- SGC 2.28
- VTYX N/A
- 52 Week Low
- SGC $9.11
- VTYX $0.78
- 52 Week High
- SGC $20.75
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- SGC 58.87
- VTYX 51.25
- Support Level
- SGC $10.21
- VTYX $1.95
- Resistance Level
- SGC $11.28
- VTYX $2.51
- Average True Range (ATR)
- SGC 0.34
- VTYX 0.16
- MACD
- SGC 0.09
- VTYX -0.06
- Stochastic Oscillator
- SGC 72.26
- VTYX 36.61
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.